Home » Stocks » Morphic Holding

Morphic Holding, Inc. (MORF)

Stock Price: $25.79 USD -0.19 (-0.73%)
Updated Jul 6, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 790.39M
Revenue (ttm) 16.50M
Net Income (ttm) -54.87M
Shares Out 30.60M
EPS (ttm) -2.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 6, 2020
Last Price $25.79
Previous Close $25.98
Change ($) -0.19
Change (%) -0.73%
Day's Open 26.48
Day's Range 25.43 - 26.48
Day's Volume 62,155
52-Week Range 9.90 - 33.50

More Stats

Market Cap 790.39M
Enterprise Value 571.10M
Earnings Date (est) Aug 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 30.60M
Float 9.30M
EPS (basic) -6.21
EPS (diluted) -2.37
FCF / Share -2.08
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 559,637
Short Ratio 8.40
Short % of Float 4.79%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 47.89
PB Ratio 5.48
Revenue 16.50M
Operating Income -58.64M
Net Income -54.87M
Free Cash Flow -62.68M
Net Cash 219.29M
Net Cash / Share 7.16
Gross Margin -222.72%
Operating Margin -355.35%
Profit Margin -332.50%
FCF Margin -379.79%
ROA -17.48%
ROE -52.08%
ROIC -60.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(15.04% upside)
Current: 25.79
Target: 29.67
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth405.57%--
Gross Profit16.983.36-
Operating Income-46.99-24.63-16.93
Net Income-43.33-23.83-16.92
Shares Outstanding16.101.071.01
Earnings Per Share-2.69-22.28-
Operating Cash Flow-41.6576.34-15.42
Capital Expenditures-2.16-0.66-0.91
Free Cash Flow-43.8175.68-16.32
Cash & Equivalents23718621.03
Total Debt--0.63
Net Cash / Debt23718620.40
Book Value141-52.55-29.69
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Morphic Holding, Inc.
Country United States
Employees 80
CEO Praveen P. Tipirneni

Stock Information

Ticker Symbol MORF
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MORF


Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidates in clinical development are MORF-720, a selective oral avß6 specific integrin inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC); and MORF-057, a a4ß7 specific integrin inhibitor for the treatment of inflammatory bowel disease (IBD). The company is also developing MR ß6 #2, a selective avß6 specific integrin inhibitor to treat IPF and PSC; and avß1 integrin for the treatment of fibrosis. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. The company was founded in 2014 and is based in Waltham, Massachusetts.